Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers

Palsgrove, Doreen N.; Allahabadi, Sameer

doi:10.1016/j.path.2020.10.001

Cited by 7 publications

(5 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is significant heterogeneity in tumors derived from the head and neck region [ 21 ]. Of these, salivary gland carcinomas are genomically different from other HNCs because they have druggable genomic alterations such as HER2 , RET , and NTRK [ 22 ]. In this study, two of the four patients who received genome-matched therapy were diagnosed with salivary gland cancer, which may have affected the results.…”

Section: Discussionmentioning

confidence: 99%

Availability of genome-matched therapy based on clinical practice

Hayashi,

Mori,

Ohmoto

et al. 2024

Int J Clin Oncol

View full text Add to dashboard Cite

Background Comprehensive genomic profiling (CGP) provides new opportunities for patients with advanced cancer to receive genome-matched therapies, but the availability rate of these remains low. We reviewed our CGP cases and suggested possible strategies to improve the current status from a clinical perspective. Methods Druggable genomic alterations and barriers to accessing genome-matched therapies were investigated in 653 patients with 30 various types of cancers who underwent CGP. Results While the availability rate of genome-matched therapies as a whole was 9.5%, CGP was useful in some cancer types. Patients with thyroid cancer and lung cancer harbored druggable genomic alterations at high rates, while sarcoma rarely harbored these alterations (100%, 76%, and 15.2%, respectively). In contrast, the availability rate of genome-matched therapies was highest in patients with sarcoma and head and neck cancer (HNC) (60% and 40%, respectively). One hundred thirteen patients (63.5%) had multiple barriers to accessing genome-matched therapy. Of 178 patients, 21 patients (11.8%) could not be considered for genome-matched therapies solely because of the deterioration of their performance status. Conclusion This study demonstrated the usefulness of CGP for patients with sarcoma and HNC in addition to lung cancer in clinical practice. Performing CGP at the front line has the potential to improve the availability of genome-matched therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Availability of genome-matched therapy based on clinical practice

Hayashi,

Mori,

Ohmoto

et al. 2024

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…The discoveries reported here can also have implications for cancer diagnosis and treatment. To date, standard treatments for salivary gland cancers include surgical resection, radiation therapy, and chemotherapeutics ( 189 ). As with all cancers, resection may allow for the recurrence of cancer, therefore necessitating radiation and/or chemotherapy in order to be effective.…”

Section: Discussionmentioning

confidence: 99%

Sci-Seq of Human Fetal Salivary Tissue Introduces Human Transcriptional Paradigms and a Novel Cell Population

et al. 2022

View full text Add to dashboard Cite

Multiple pathologies and non-pathological factors can disrupt the function of the non-regenerative human salivary gland including cancer and cancer therapeutics, autoimmune diseases, infections, pharmaceutical side effects, and traumatic injury. Despite the wide range of pathologies, no therapeutic or regenerative approaches exist to address salivary gland loss, likely due to significant gaps in our understanding of salivary gland development. Moreover, identifying the tissue of origin when diagnosing salivary carcinomas requires an understanding of human fetal development. Using computational tools, we identify developmental branchpoints, a novel stem cell-like population, and key signaling pathways in the human developing salivary glands by analyzing our human fetal single-cell sequencing data. Trajectory and transcriptional analysis suggest that the earliest progenitors yield excretory duct and myoepithelial cells and a transitional population that will yield later ductal cell types. Importantly, this single-cell analysis revealed a previously undescribed population of stem cell-like cells that are derived from SD and expresses high levels of genes associated with stem cell-like function. We have observed these rare cells, not in a single niche location but dispersed within the developing duct at later developmental stages. Our studies introduce new human-specific developmental paradigms for the salivary gland and lay the groundwork for the development of translational human therapeutics.

show abstract

“…[17][18][19] Known molecular markers in CXPA include PLAG1 and HMGA2 fusion genes, p53, hormonal receptors, HER2, and ERBB mutations. 1,10,11,[20][21][22] Although multiple reviews have been published on salivary gland tumours, 7,10,13,18,23 including CXPA, 10,13,23,24 it has been a decade since the last dedicated systematic review pertaining to molecular genetics in CXPA was published. 1 Existing reviews on important biomarkers, such as PD-L1, 25 PLAG1, 12 and other targeted therapies, 18,19 do not address CXPA as a distinct entity.…”

Section: Introductionmentioning

confidence: 99%

“…Existing literature suggests high potential for targeted therapies in CXPA, 15,16 particularly because the molecular genetics underlying the malignant transformation from pleomorphic adenoma, to carcinoma ex pleomorphic adenoma (CXPA), has been an ongoing area of interest 17–19 . Known molecular markers in CXPA include PLAG1 and HMGA2 fusion genes, p53, hormonal receptors, HER2, and ERBB mutations 1,10,11,20–22 …”

Section: Introductionmentioning

confidence: 99%

Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta‐Analysis

Key,

Chia,

Hasan

et al. 2023

The Laryngoscope

View full text Add to dashboard Cite

ObjectiveCarcinoma ex pleomorphic adenoma (CXPA) is a rare malignant salivary gland tumor. Although multiple reviews have been published on salivary gland malignancies, it has been a decade since the last dedicated systematic review pertaining to CXPA alone was published. This study examines molecular factors in CXPA diagnosis.Data SourcesMEDLINE, CINAHL, Embase, Scopus, Web of Science (BIOSIS), Cochrane CENTRAL, Health Collection (Informit), OpenDOAR, and GreyNet International.Review MethodsSystematic review and meta‐analysis from inception to October 31, 2022 for all English language studies pertaining to “carcinoma ex pleomorphic adenoma.” Predicted incidence of each biomarker was calculated with meta‐analysis. Comparison against pleomorphic adenoma (PA) and salivary duct carcinoma (SDC) when reported within the same study are performed. Risk of bias performed with JBI tool for prevalence studies.ResultsOf 19151 unique studies undergoing abstract screening, 55 studies (n = 1322 patients) underwent data analysis. Biomarkers with >3 studies were p53, HER2, AR, EGFR, PLAG1, ERBB, ER, PR, HMGA2, p16, p63, a‐SMA, RAS, PTEN, PDL1, BRAF, PIK3CA, and c‐kit. Highest incidence was seen in AR, EGFR, p16, and p53. Significant differences were demonstrated compared with PA and SDC. There was high heterogeneity and overall high risk of bias within studies.ConclusionMolecular factors are an area of interest in the diagnosis of CXPA. Our study results support examining CXPA as a discrete cohort in future targeted therapy trials. Laryngoscope, 2023

show abstract

Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers

Cited by 7 publications

References 85 publications

Availability of genome-matched therapy based on clinical practice

Availability of genome-matched therapy based on clinical practice

Sci-Seq of Human Fetal Salivary Tissue Introduces Human Transcriptional Paradigms and a Novel Cell Population

Molecular Factors in Carcinoma Ex Pleomorphic Adenoma: Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About